Investigating the Effectiveness and Safety of Combining Thrombopoietin Receptor Agonist and Immunosuppressant Drugs for Patients with Multirefractory Immune Thrombocytopenia after Second-Line Monotherapy Treatments

被引：0

作者：

Mingot-Castellano, Maria Eva ^{[1
]}

Mellado, Patricia Alcalde ^{[1
]}

Urena, Laura Entrena ^{[2
]}

Izquierdo, Maria Cristina Pascual ^{[3
]}

Zafra, Denis ^{[4
]}

Hinryk, Mariana Canaro ^{[5
]}

Bastida, Jose Maria ^{[6
]}

Bernat, Silvia Bernat ^{[7
]}

Carballeira, Daniel Martinez ^{[8
]}

Miranda, Isabel Caparros ^{[9
]}

Garcia, Amalia Cuesta ^{[10
]}

Lakhwani, Sunil ^{[11
]}

Gonzalez, Blanca Sanchez ^{[12
]}

Maldonado, Marta Canet ^{[13
]}

Solano, Maria Carmen Gomez del Castillo ^{[14
]}

Culebra, Marta Garcia ^{[1
]}

Rodriguez, Beatriz Chiclana ^{[1
]}

Fernanadez-Villalobos, Manuel ^{[15
]}

Llorca, Paula Sanchez ^{[16
]}

Monsonis, Lola Piquer ^{[17
]}

Vazquez, Carlos Puerta ^{[18
]}

Montes, Rocio Perez ^{[10
]}

Garcia-Pallarols, Francesc ^{[19
]}

Valcarcel, David ^{[20
]}

Amador, Begona Pedrote ^{[1
]}

机构：

[1] Univ Seville, Hosp Univ Virgen Rocio, Inst Biomed Sevilla, Seville, Spain

[2] Hosp Univ Virgen Nieves, Granada, Spain

[3] Hosp Univ Gregorio Maranon, Serv Hematol, Inst Invest Gregorio Maranon, Madrid, Spain

[4] Hosp Univ 12 Octubre, Madrid, Spain

[5] Hosp Univ Son Espases, Hematol Dept, IdISBa, Palma De Mallorca, Spain

[6] Hosp Clin Univ Salamanca, Hematol Dept, IBSAL, Salamanca, Spain

[7] Hosp Univ Plana, Villarreal, Castellon, Spain

[8] Hosp Univ Cent Asturias, Oviedo, Asturias, Spain

[9] Univ Malaga, E-29071 Malaga, Spain

[10] Hosp Sierrallana, Torrelavega, Spain

[11] Hosp Univ Canarias, San Cristobal la Laguna, Spain

[12] Hosp Mar, Hematol Dept, Barcelona, Spain

[13] Hosp Universitari Mutua Terrassa, Terrassa, Barcelona, Spain

[14] Complexo Hospitalario Univ A Coruna, La Coruna, Spain

[15] Hosp Gen Univ Gregorio Maranon, Madrid, Spain

[16] Hosp 12 Octubre, Madrid, Spain

[17] Hosp Univ Son Espases, Mallorca, Spain

[18] Complejo Asistencial Univ Salamanca CAUSA, IBSAL, Salamanca, Spain

[19] Hosp Mar, Barcelona, Spain

[20] Hosp Univ Hebron, Dept Hematol, Barcelona, Spain

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-201847

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：3948 / 3949

页数：2

共 37 条

[31] VAYHIT3: An Open-Label, Single-Arm, Phase II Trial to Evaluate the Efficacy and Safety of Ianalumab in Patients with Primary Immune Thrombocytopenia (ITP) Previously Treated with at Least 1 Corticosteroid and 1 Thrombopoietin Receptor Agonist (TPO-RA)
Kuter, David J.
Bradbury, Charlotte A.
Allepuz, Alex
Pfender, Nadege
Haenig, Jens
Nowak, Claus
Jose Gonzalez-Lopez, Tomas
BLOOD, 2023, 142
[32] A randomized, open-label study of the efficacy and safety of galinpepimut-S (GPS) maintenance monotherapy compared to investigator's choice of best available therapy (BAT) in patients with acute myeloid leukemia (AML) who have achieved complete remission (CR) after second-line salvage therapy
Jamy, Omer Hassan
Khan, Sharif S.
Tsirigotis, Panagiotis
Tomlinson, Benjamin Kent
Hunault-Berger, Mathilde
Platzbecker, Uwe
Sakellari, Ioanna
Vidovic, Ana
Montesinos, Pau
del Castillo, Teresa Bernal
Egan, Daniel
Safah, Hana
Schiller, Gary J.
Haenel, Mathias
Obara, Agata
Chen, Tsung-Chih
Rotta, Marcello
Giannouli, Stavroula
Savic, Aleksandar
Cicic, Dragan
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[33] Outcomes of patients with metastatic renal cell carcinoma (mRCC) who were treated with second-line (2L) vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKI) after first-line (1L) immune checkpoint inhibitor (ICI) therapy
Shah, A. Y.
Lemke, E. A.
Jianjun, G.
Chandamohan, A.
Campbell, M. T.
Saavedra, A. Zurita
Xiao, L.
Wang, J.
Corn, P. G.
Jonasch, E.
Sharma, P.
Tannir, N.
ANNALS OF ONCOLOGY, 2017, 28
[34] A phase II, randomized, double-blind, placebo-controlled trial evaluating efficacy and safety of namodenoson (CF102), an A3 adenosine receptor agonist (A3AR), as a second-line treatment in patients with Child-Pugh B (CPB) advanced hepatocellular carcinoma (HCC).
Stemmer, Salomon M.
Manojlovic, Nebojsa S.
Marinca, Mihai Vasile
Petrov, Petar
Cherciu, Nelly
Ganea, Doina
Ciuleanu, Tudor-Eliade
Puscas, Ioana Adriana
Beg, Muhammad Shaalan
Purcell, William T.
Croitoru, Adina-Emilia
Ilieva, Rumyana Nedyalkova
Natosevic, Sladjana
Nita, Amedeia Lavinir
Kalev, Dimitar Nikolaev
Harpaz, Zivit
Farbstein, Motti
Silverman, Michael H.
Fishman, Pnina
Llovet, Josep M.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[35] Outcomes of patients (pts) with metastatic clear-cell renal cell carcinoma (mCCRCC) treated with second-line (2L) vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKI) after first-line (1L) immune checkpoint inhibitors (ICI).
Shah, Amishi Yogesh
Lemke, Emily
Gao, Jianjun
Chandramohan, Anuradha
Campbell, Matthew T.
Zurita, Amado J.
Xiao, Lianchun
Wang, Jennifer
Corn, Paul Gettys
Jonasch, Eric
Sharma, Padmanee
Tannir, Nizar M.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
[36] Efficacy and safety of docetaxel (D) vs androgen-receptor signaling inhibitors (ARSi) as second-line therapy (Rx) after progression on alternative ARSi as first-line Rx for patients who are elderly (≥75 years old) with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter international database: A SPARTACUSS- Meet-URO 26 study.
Gennusa, Vincenzo
Saieva, Calogero
Lee-Ying, Richard M.
Nuzzo, Pier Vitale
Spinelli, Gian Paolo
Zanardi, Elisa
Fotia, Giuseppe
Rossetti, Sabrina
Valenca, Loana Bueno
Patrikidou, Anna
Andrade, Livia
Mestre, Ricardo Pereira
Fornarini, Giuseppe
Procopio, Giuseppe
Santini, Daniele
Sweeney, Christopher
Heng, Daniel Yick Chin
De Giorgi, Ugo
Russo, Antonio
Francini, Edoardo
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[37] Second-line Therapy for Patients with locally advanced or metastatic Urothelial Carcinoma. An open, multi-centric Study for Assessing the Safety of a Fixed-Dose Combination Therapy with Durvalumab plus Tremelimumab or Monotherapy with Durvalumab for treating solid Malignancies (STRONG) in advanced Stage - Module A - urothelial and non-urothelial Carcinomas of the Urinary Tract after Chemotherapy - AB 60/17 AUO
Rexer, H.
Merseburger, A.
Grohe, C.
UROLOGE, 2018, 57 (03): : 374 - 375

← 1 2 3 4 →